FWIW, I took Tirzepatide for several weeks with no side effects.
It killed my appetite for months after I stopped taking it.
For me it was the opposite. I had severe side effects especially back pain to the point of walking crooked. I stopped Tirze and started Reta and the pain has started to get better. As far as appetite suppression, I thought they both had about same effect, they basically did what they were supposed to, but with RETA I would get the feeling of being full faster, and often times would leave food on the plate (never happens in real life).
Did you ever try semaglutide? Tirz feels better than sema. I almost jumped from sema to reta but I’m glad I chose tirz. I can always move to reta later, or maybe even add in 1mg of reta a week on top of what I’m already doing.
I’m a believer in tirzepatide. I’m effortlessly ripped and have immaculate blood test results.
If anything I should eat more food. I don’t need to lose weight anymore I can just maintain. It’s a weird feeling in a world full of people desperate to control their desires and lose weight, I have the luxury of the opposite.
5 Likes
Well, everyone or most using GLP!'s is in the same boat as you, and no I didn’t try Sema. Started with Reta then switched to Tirze (over the concern that Reta is not FDA approved yet) and switched back to Reta, but do 3times @1.3 per week as opposed to once weekly. Very few sides and my back pain (which got worse on Tirze) has almost disappeared on Reta.
6 Likes
One more paper showing depression risk with Ozempic: Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data 2025
Only semaglutide demonstrated statistically significant SDRs for depressive disorders in both databases (FAERS: ROR 1.26, 95% confidence interval (CI) 1.15–1.37; IC 0.33, 95% CI 0.20–0.45; VigiBase: ROR 1.38, 95% CI 1.27–1.49; IC 0.46, 95% CI 0.34–0.57), while liraglutide and tirzepatide showed no SDRs. Stratified analyses revealed increased disproportionality in females and healthcare professional reports. WSP analysis showed semaglutide-associated depression followed an early failure pattern, with no significant drug interactions identified with psychotropic medications.
1 Like
I think I felt a bit of depression on semaglutide compared to tirzepatide.
I theorized that semaglutide helping control cravings didn’t immediately overcome the emotional satiation giving into those cravings supplied. But if the information you’ve presented is true then perhaps my theory was not correct.
1 Like
I think I can pretty much confirm that 10 months of Retatrutide has reduced the size of my left atrium, after it used to be mildly enlarged. It was already shrinking one month into taking it, and it’s even smaller now, well into the normal range. This should greatly reduce any risk of Afib. 3mg has been my dose for the majority of the time.
I wasn’t sure if the last time was a random technician measuring it differently on the echocardiogram, but now I’m confident it’s real.
This finding is consistent with the evidence. Very good news.
7 Likes
Do we have evidence that retatrutide lowers left atrial volume more than other GLP-1RAs?
(I only found this: The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis 2024)
5 Likes
I don’t think they tested them each individually so I think they all probably can, which is good news.
Do you take an SGLT2i as well, and/or telmisartan? All 3 can reverse pathologic LV remodeling/hypertrophy, presumably moreso when used together.
3 Likes
Yes but I’ve been taking those for many years and get echocardiograms once per year. It wasn’t until I added Retatrutide that I saw my left atrial volume decreasing.
5 Likes
Everybody says that GLP-1RA are amazing drugs and people are getting miraculous results. I guess that’s true. Still, maybe I’m just overly conservative (but I take rapamycin, lol), but I’m wondering about the long term effects. For now, I feel as if we don’t quite know enough about them for me to feel comfortable enough to take the plunge. I contrast that with SGLT2i, on which we also don’t have super long term data, but which strike me as in some ways safer and simpler to understand (although by no means do we understand them fully!). On the GLP-1 we have reports of inexplicable ocular events, rare(?) but dire gut issues, paresthesia, and so on. SGLT2i have genital infections (empagliflozin minimal), and not a great deal more unless combined with other drugs. Somehow I feel subjectively that SGLT2i are simpler and safer.
But clearly, I’m rather in a definite minority in this caution, so I’m wondering how people think of the issue of safety here? By no means am I suggesting that I’m right to be cautious, just curious.
1 Like
Just chiming in here on my N=1 experience with semaglutide (rybelsus), as there has been discussion of the possible adverse effects.
Took the trainer dose-- not even the starting 7 mg – and the effect was so overwhelming – went from about 104 to 96 pounds in a couple of weeks – and experienced bad back pain and a whopping 15,000+/ WBC. It turned out to be gall stones. Now I know: when you lose weight very rapidly it causes the liver to respond with changes to bile and that leads to the gall stones. Now, much later, I have discovered that if you take TUDCA you can head off the liver-related negatives.
4 Likes
First approval:
- GLP-1RA: 2005 (exenatide)
- SGLT2i: 2013 (canagliflozin)
I think we have all the data needed in terms of safety. It’s just that the benefits are not yet clear among non diabetics / non overweight and we don’t have longevity studies other than one preprint in worms (iirc).
5 Likes
Everything beats being obese and/or diabetic. If you’re neither of them, just use SGLT2i.
3 Likes
OMG I can’t believe they publish this crap. Talk about a shitty journal.
3 Likes
Nature is a shitty journal? ok…
1 Like
Really didn’t think compounding would be thriving even 3 months ago. But all signs are pointing to compounded GLP1 staying around :
5 Likes